Literature DB >> 12413637

Bone mineral density and prolactin associations in patients with chronic schizophrenia.

George Abraham1, Uriel Halbreich, Ronald H Friedman, Richard C Josiassen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12413637     DOI： 10.1016/s0920-9964(01)00321-8

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  12 in total

Review 1.  Osteoporosis and fracture risk in people with schizophrenia.

Authors:  Taishiro Kishimoto; Marc De Hert; Harold E Carlson; Peter Manu; Christoph U Correll
Journal:  Curr Opin Psychiatry       Date:  2012-09       Impact factor: 4.741

2.  Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients.

Authors:  Jenn-Huei Renn; Nan-Ping Yang; Pesus Chou
Journal:  BMC Musculoskelet Disord       Date:  2010-02-17       Impact factor: 2.362

3.  Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment.

Authors:  Jeffrey R Bishop; Leah H Rubin; James L Reilly; Mani N Pavuluri; John A Sweeney
Journal:  Ther Adv Psychopharmacol       Date:  2012-06

Review 4.  Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation.

Authors:  Uriel Halbreich
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment.

Authors:  Oliver D Howes; Michael J Wheeler; Anna-Maria Meaney; Veronica O'Keane; Ignac Fogelman; Glen Blake; Robin M Murray; Shubulade Smith
Journal:  J Clin Psychopharmacol       Date:  2005-06       Impact factor: 3.153

Review 6.  Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review.

Authors:  Frank M C Besag; Michael J Vasey; Iffah Salim
Journal:  CNS Drugs       Date:  2021-04-20       Impact factor: 5.749

7.  Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study.

Authors:  Tae-Young Lee; Moon-Yong Chung; Hae-Kyung Chung; Jin-Hee Choi; Tae-Yong Kim; Hyung-Seok So
Journal:  Psychiatry Investig       Date:  2010-11-30       Impact factor: 2.505

8.  Effect of age and disease on bone mass in Japanese patients with schizophrenia.

Authors:  Norio Sugawara; Norio Yasui-Furukori; Takashi Umeda; Shoko Tsuchimine; Akira Fujii; Yasushi Sato; Manabu Saito; Hanako Furukori; Kazuma Danjo; Masashi Matsuzaka; Ippei Takahashi; Sunao Kaneko
Journal:  Ann Gen Psychiatry       Date:  2012-02-20       Impact factor: 3.455

9.  Osteoporosis associated with antipsychotic treatment in schizophrenia.

Authors:  Haishan Wu; Lu Deng; Lipin Zhao; Jingping Zhao; Lehua Li; Jindong Chen
Journal:  Int J Endocrinol       Date:  2013-04-17       Impact factor: 3.257

10.  Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Authors:  Deanna L Kelly; Heidi J Wehring; Amber K Earl; Kelli M Sullivan; Faith B Dickerson; Stephanie Feldman; Robert P McMahon; Robert W Buchanan; Dale Warfel; William R Keller; Bernard A Fischer; Joo-Cheol Shim
Journal:  BMC Psychiatry       Date:  2013-08-22       Impact factor: 3.630
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.